// App-Quantinova.ai

3398 : Effectiveness and Safety of Apixaban Vs Warfarin Among Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Obesity

Researchers

Presenter

  • Alexander T Cohen

Principal Investigators

  • Janvi Sah

  • Theodore Lee

  • Gail Wygant

  • Lisa Rosenblatt

  • Patrick Hlavacek

  • Birol Emir

  • Allison Keshishian

  • Rachel Delinger

  • Xuemei Luo

Medical Centers

  • Department of Haematological Medicine, Guy's and St Thomas Hospitals, King's College, London, United Kingdom

  • Department of Hematological Medicine, Guys and St Thomas/NHS Foundation Trust, London, GBR

  • STATinMED Research, Ann Arbor, MI

  • Pfizer Inc, New York, NY

  • Bristol-Myers Squibb, Lawrenceville, NJ

  • Pfizer Inc, New York, NY

  • Pfizer Inc, New York, NY

  • Pfizer, Groton, CT

Locations

  • United Kingdom

  • United States

Companies

  • Bristol-Myers Squibb

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Venous thrombosis

  • Obesity

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxyzine

  • apixaban

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved